WILEX AG / Research Update
17.06.2010 08:41
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
WILEX successfully completed Phase I study with the MEK inhibitor WX-554
Munich, Germany, 17 June 2010. WILEX AG (ISIN DE0006614720 / WL6 /
Frankfurt Stock Exchange) successfully completed a Phase I dose escalation
study with the MEK inhibitor WX-554 demonstrating for the first time WX-554
activity in humans.
The trial aimed to determine safety, tolerance and the optimal biological
dose for the inhibition of the MEK system by WX-554. The study, which was
conducted in Germany, tested five increasing dose levels, each administered
once by a 15 min infusion of WX-554 in five healthy male volunteers.
In addition to safety and tolerance, the pharmacokinetic and
pharmacodynamic properties of the MEK inhibitor were also investigated. The
substance was safe and well tolerated in the 25 healthy volunteers. The MEK
signal transduction pathway was inhibited in a dose-dependent matter
reaching complete inhibition at 1 mg/kg body weight.
Dr. Paul Bevan, Head of Research and Development and member of the
Executive Management Board of WILEX AG, commented: 'We are delighted with
the positive results of WX-554 in this study. With it we have a further
product in our clinical pipeline which, due to its mechanism of action,
could be used in many oncological indications. We will now initiate the
further development of this promising agent with the clinical testing of an
oral formulation.'
About WX-554
The orally available, small-molecule MEK inhibitor is one of five oncology
preclinical programmes obtained under the strategic alliance agreed with
UCB in January 2009. Mitogen activated protein kinase (MEK) has been shown
to play a central role in signal transduction. MEK has been linked to a
multitude of biological processes such as cell division, cell
differentiation and cell death. The MEK signalling pathway is over
expressed in more than 30% of cancers, resulting in uncontrolled cell
growth and proliferation.
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich and is listed at
the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.
WILEX's mission is to develop drugs with a low side effect profile and
targeted treatment of different types of cancer as well as diagnostic
agents for specific detection of tumours. The Company's product candidates
are based on antibodies and small molecules. WILEX has an attractive
product pipeline which includes both drug and diagnostic candidates: A
pivotal Phase III study with REDECTANE(R) has been completed and positive
data published. RENCAREX(R) is undergoing a Phase III registration trial.
Positive MESUPRON(R) Phase II data in the indication pancreatic cancer have
been published and another Phase II trial in breast cancer is ongoing. A
further oncology project (PI3K inhibitor WX-037) is in preclinical
development and three antibody programmes are in research. WILEX aims
within a few years to be able to finance its research and development
programmes from its operating cash flow. Website: http://www.WILEX.com,
ISIN DE0006614720 / WKN 661472 / Symbol WL6
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Mobile: +49 (0)160-93 60 30 22
Email: investors@wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
17.06.2010 08:41 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: WILEX AG: WILEX successfully completed Phase I study with the MEK inhibitor WX-554
| Source: EQS Group AG